To investigate whether dual treatment may be effective for CML patients who do not respond adequately to single TKI treatment, we performed viability and apoptosis assays on CD34+ stem/progenitor cells obtained at diagnosis from CML patients classified retrospectively as IM-nonresponders (n = 4, Supplementary Table 1)[45, 46]. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.